The UK's Living Research Landscape
The United Kingdom has quietly become one of the most active places in the world for diabetes research. From the NHS Type 2 Diabetes Path to Remission Programme (the "soups and shakes" diet that has helped thousands of patients lose weight and, in some cases, put their diabetes into remission) to cutting-edge immunotherapies that can delay type 1 diabetes, the pipeline of studies recruiting across England, Scotland, Wales and Northern Ireland is busy.
In the Midlands alone, more than 3,000 people were enrolled onto the NHS remission programme in 2024-25, with average weight loss around 11% of total body weight — double the previous year's numbers. Researchers are now testing whether these real-world results hold up in longer follow-ups, and the evidence keeps building.
What Kinds of Trials Are Recruiting?
The modern UK diabetes trial scene splits into several distinct streams, each with its own goals and participants.
Weight-led remission research. The NHS Path to Remission programme, built on total diet replacement, remains a focus of evaluation. Studies tracking participants over time are looking at whether remission can be sustained, which patients benefit most, and how the programme performs outside tightly controlled clinical settings.
Technology and glucose monitoring. Continuous glucose monitoring (CGM) is arguably the hottest area in UK diabetes research right now. A landmark randomised controlled trial called FreeDM2, run across 24 UK sites with 303 participants, showed that people with type 2 diabetes on basal insulin who used FreeStyle Libre technology saw a 0.6% greater reduction in HbA1c and spent about 2.5 more hours per day in a healthy glucose range compared with those relying on finger pricking. The study, presented in March 2026, helped expand the case for CGM beyond people on intensive insulin regimens.
Another notable study, the Dexcom primary care trial registered with ISRCTN, is testing how continuous glucose monitoring can be initiated and managed in routine GP settings across the UK and Ireland for people with type 2 diabetes who use insulin. It is actively recruiting adults aged 18 and over who have had a type 2 diabetes diagnosis for at least three months.
Immunotherapy and disease-modifying treatment. For type 1 diabetes, the picture is shifting. NICE approved teplizumab for NHS use in June 2026 after it was used under an early access scheme in Birmingham — the first UK site to administer it. This immunotherapy, given as a daily hospital infusion for 14 days, can delay progression to insulin-requiring type 1 diabetes in people at stage 2 of the condition. Researchers at the University of Birmingham and elsewhere continue to recruit for related studies exploring how the immune system attacks insulin-producing beta cells.
Everyday behaviour and prevention. Not all trials involve drugs or devices. Studies at universities like Roehampton, Coventry and Birmingham are recruiting people with prediabetes and type 2 diabetes to examine protein intake, meal timing, healthy eating habits and digital tools. The GLOWING study at the University of Birmingham, for instance, is looking at whether pre-meal protein drinks can improve blood sugar levels in adults aged 70 to 90 living with type 2 diabetes.
A Quick Guide to Major Trial Types
| Trial type | Example in the UK | What participants do | Best suited to | Potential benefits | Practical considerations |
|---|
| Diet/remission | NHS Path to Remission evaluation | Structured meal replacement and support | Adults 18-65 with recent type 2 diagnosis | Possible remission, significant weight loss | Requires commitment to a strict diet phase |
| CGM technology | FreeDM2, Dexcom primary care study | Wear a sensor, review glucose data | People with type 2 on insulin or at risk | Better glucose control, fewer finger pricks | Sensor wear may feel unfamiliar at first |
| Immunotherapy | Teplizumab-related studies | 14-day hospital infusions | People with stage 2 type 1 diabetes | Delayed progression to insulin dependence | Hospital visits over two weeks |
| Prevention/behaviour | GLOWING, prediabetes studies | Questionnaires, in-person sessions, dietary changes | People with prediabetes or early diabetes | Practical habits that support long-term health | Often time-bound, location dependent |
How to Find and Join a Trial in the UK
If a trial sounds like a fit, the route in is more straightforward than many people expect.
Start with your diabetes team. Your GP or specialist nurse knows your history and can tell you whether you meet the broad eligibility criteria for studies in your area. Many NHS trusts also run research departments that advertise open studies locally.
Check the national registries. The NHS's "Be Part of Research" service lists trials by condition and postcode. ClinicalTrials.gov and the ISRCTN registry both cover UK studies, though some industry-sponsored work is only listed on one. Diabetes UK maintains a dedicated clinical trials page that is updated regularly, and Breakthrough T1D (formerly JDRF) lists type 1 research opportunities specifically.
Look at university and hospital research pages. The University of Birmingham, King's College Hospital, Hull University Teaching Hospitals and Oxford Brookes are just a few institutions actively recruiting. Each study page explains what participation involves, whether travel is needed, and how to contact the study team directly.
Ask the practical questions. Before signing up, it is worth clarifying how many visits are involved, whether travel costs are covered, how your data will be protected, and what happens at the end of the study. Trial teams are used to these questions and expect them.
What Participants Can Expect
Participation varies widely. Some studies, like the digital behaviour projects, can be done largely from home with occasional questionnaires. Others, such as the immunotherapy infusions or CGM trials, involve regular clinical contact. Most trials provide the intervention at no cost to the participant as part of the research, and many reimburse reasonable travel expenses — though the details differ from study to study, so it is always worth confirming.
What participants consistently report, though, is that the experience gives them more than data points. People often describe gaining a deeper understanding of their own glucose patterns, access to technologies and specialists they might not otherwise encounter, and the quiet satisfaction of contributing to treatments their children and grandchildren may one day rely on.
The Road Ahead
UK diabetes research is entering an unusually rich period. Remission is no longer a theoretical idea. CGM is moving from specialist clinics into everyday GP care. An immunotherapy that can delay type 1 diabetes is now available on the NHS. Each of these advances began with people willing to take part in a trial — often simply because a researcher asked.
If you live with diabetes, or care for someone who does, that invitation extends to you. The registries are searchable, the study teams are approachable, and the eligibility criteria are far broader than most people assume. Whether you are 18 or 90, newly diagnosed or twenty years in, there is likely a study somewhere in the UK that wants exactly what you can offer: your lived experience, your time, and your willingness to help build the evidence base for better care.
研究の知恵